Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

18 Aug 2023
endpts.com
Phase 3Clinical Result
Merck said Friday morning that its HIF-2α inhibitorHIF-2α inhibitor Welireg met the co-primary endpoint of progression-free survival in a Phase III trial for patients with advanced forms of renal cell carcinoma, but it did not meet the other co-primary endpoint of overall survival.
The topline data come from a head-to-head Phase III trial with everolimus, also known as Novartis’ Afinitor, testing Welireg in pre-treated patients with advanced forms of renal cell carcinoma.
Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.